[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA38126A1 - 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8 - Google Patents

6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8

Info

Publication number
MA38126A1
MA38126A1 MA38126A MA38126A MA38126A1 MA 38126 A1 MA38126 A1 MA 38126A1 MA 38126 A MA38126 A MA 38126A MA 38126 A MA38126 A MA 38126A MA 38126 A1 MA38126 A1 MA 38126A1
Authority
MA
Morocco
Prior art keywords
tarp
dependent
receptor antagonist
amfa
benzothiazol
Prior art date
Application number
MA38126A
Other languages
English (en)
Other versions
MA38126B1 (fr
Inventor
Jon Kevin Reel
Warren Jaye Porter
Jeffrey Michael Witkin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA38126A1 publication Critical patent/MA38126A1/fr
Publication of MA38126B1 publication Critical patent/MA38126B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un antagoniste du récepteur ampa dépendant de tarp ?8 de formule : (i), ses sels pharmaceutiquement acceptables, ses utilisations et ses procédés de préparation.
MA38126A 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8 MA38126B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730273P 2012-11-27 2012-11-27
PCT/US2013/070885 WO2014085153A1 (fr) 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}- éthyl)-3h-1,3-benzothiazol-2-one utilisable en tant qu'antagoniste du récepteur ampa dépendant de tarp-gamma

Publications (2)

Publication Number Publication Date
MA38126A1 true MA38126A1 (fr) 2017-03-31
MA38126B1 MA38126B1 (fr) 2017-11-30

Family

ID=49753484

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38126A MA38126B1 (fr) 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8

Country Status (36)

Country Link
US (1) US8765960B2 (fr)
EP (1) EP2925754B1 (fr)
JP (1) JP6246227B2 (fr)
KR (1) KR101693133B1 (fr)
CN (1) CN104797578B (fr)
AP (1) AP2015008489A0 (fr)
AR (1) AR093527A1 (fr)
AU (1) AU2013352594B2 (fr)
BR (1) BR112015011200A2 (fr)
CA (1) CA2889243C (fr)
CL (1) CL2015001419A1 (fr)
CR (1) CR20150267A (fr)
CY (1) CY1118657T1 (fr)
DK (1) DK2925754T3 (fr)
DO (1) DOP2015000113A (fr)
EA (1) EA026686B1 (fr)
ES (1) ES2618260T3 (fr)
HK (1) HK1209116A1 (fr)
HR (1) HRP20170274T1 (fr)
HU (1) HUE033447T2 (fr)
IL (1) IL238831B (fr)
JO (1) JO3225B1 (fr)
MA (1) MA38126B1 (fr)
MX (1) MX356478B (fr)
MY (1) MY177721A (fr)
PE (1) PE20151728A1 (fr)
PH (1) PH12015501154A1 (fr)
PL (1) PL2925754T3 (fr)
PT (1) PT2925754T (fr)
SG (1) SG11201504164VA (fr)
SI (1) SI2925754T1 (fr)
TN (1) TN2015000200A1 (fr)
TW (2) TWI618705B (fr)
UA (1) UA114345C2 (fr)
WO (1) WO2014085153A1 (fr)
ZA (1) ZA201503733B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
US10513523B2 (en) 2015-04-29 2019-12-24 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
CR20170484A (es) * 2015-04-29 2018-02-26 Jansen Pharmaceutical Nv Azabenzimidazoles y su uso como moduladores del receptor ampa
CN107635970B (zh) * 2015-04-29 2021-03-12 詹森药业有限公司 苯并咪唑酮和苯并噻唑酮化合物以及它们作为ampa受体调节剂的用途
KR20170141769A (ko) 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 인돌론 화합물 및 ampa 수용체 조절제로서의 이의 용도
CN109963851B (zh) * 2016-10-26 2021-11-30 詹森药业有限公司 融合的双环吡啶化合物及其作为ampa受体调节剂的用途
RU2650523C1 (ru) * 2017-07-24 2018-04-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Производное пиридоксина для лечения эпилепсии
RU2703286C1 (ru) * 2019-06-18 2019-10-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Соли (5-гидрокси-3,4-бис(гидроксиметил)-6-метилпиридин-2-ил)метансульфокислоты и способ их получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
JP2000281676A (ja) * 1999-01-25 2000-10-10 Yamanouchi Pharmaceut Co Ltd Ａｍｐａ拮抗化合物の新規製造法
KR100850728B1 (ko) * 2000-06-12 2008-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 1,2-디하이드로피리딘 화합물, 그의 제조 방법 및 그의 용도
US8995993B2 (en) * 2000-10-11 2015-03-31 Gogo Llc System for managing mobile internet protocol addresses in an airborne wireless cellular network
AU2005316313B2 (en) * 2004-12-17 2011-09-29 Eli Lilly And Company Novel MCH receptor antagonists
WO2007076161A2 (fr) 2005-12-27 2007-07-05 Myriad Genetics, Inc Composés ayant une activité thérapeutique
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
CA2739559A1 (fr) * 2008-10-08 2010-04-15 Pfizer Inc. Tetrahydrofuranyl sulfonamides et compositions pharmaceutiques a base de celles-ci
PT2385938E (pt) * 2009-01-12 2015-06-02 Pfizer Ltd Derivados de sulfonamida
US8513291B2 (en) * 2010-06-01 2013-08-20 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
US9527807B2 (en) * 2011-04-05 2016-12-27 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物

Also Published As

Publication number Publication date
AU2013352594A1 (en) 2015-06-04
AU2013352594B2 (en) 2016-02-18
PL2925754T3 (pl) 2017-07-31
SI2925754T1 (sl) 2017-02-28
PH12015501154B1 (en) 2015-08-10
CN104797578A (zh) 2015-07-22
MX356478B (es) 2018-05-30
KR20150070401A (ko) 2015-06-24
IL238831B (en) 2018-08-30
MX2015006697A (es) 2015-08-05
TWI618705B (zh) 2018-03-21
CL2015001419A1 (es) 2015-10-02
DOP2015000113A (es) 2015-06-15
CA2889243C (fr) 2017-06-13
KR101693133B1 (ko) 2017-01-04
EP2925754B1 (fr) 2016-12-28
CN104797578B (zh) 2016-11-23
TW201434834A (zh) 2014-09-16
US20140148441A1 (en) 2014-05-29
JO3225B1 (ar) 2018-03-08
DK2925754T3 (en) 2017-02-20
ES2618260T3 (es) 2017-06-21
MA38126B1 (fr) 2017-11-30
HUE033447T2 (en) 2017-11-28
EA201590823A1 (ru) 2015-08-31
EP2925754A1 (fr) 2015-10-07
ZA201503733B (en) 2017-09-27
SG11201504164VA (en) 2015-07-30
CR20150267A (es) 2015-09-16
HRP20170274T1 (hr) 2017-04-07
PH12015501154A1 (en) 2015-08-10
HK1209116A1 (en) 2016-03-24
CA2889243A1 (fr) 2014-06-05
EA026686B1 (ru) 2017-05-31
AR093527A1 (es) 2015-06-10
AP2015008489A0 (en) 2015-05-31
UA114345C2 (uk) 2017-05-25
US8765960B2 (en) 2014-07-01
JP6246227B2 (ja) 2017-12-13
BR112015011200A2 (pt) 2017-07-11
TW201825484A (zh) 2018-07-16
TN2015000200A1 (en) 2016-10-03
PT2925754T (pt) 2017-02-27
WO2014085153A1 (fr) 2014-06-05
MY177721A (en) 2020-09-23
CY1118657T1 (el) 2017-07-12
JP2016501219A (ja) 2016-01-18
WO2014085153A8 (fr) 2014-07-31
PE20151728A1 (es) 2015-12-02
IL238831A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
MA38126A1 (fr) 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA37405A1 (fr) Composés hétérocyclyle
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
MX2012006909A (es) LIGANDOS DEL RECEPTOR NICOTINICO NEURONAL A4ß2 DE ACETILCOLINA.
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
UA110128C2 (uk) Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди
DE602007012313D1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate
MA35188B1 (fr) Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2
EA201170074A1 (ru) Изохинолиноновые производные в качестве антагонистов nk3
MA34663B1 (fr) Composés 3-phénylsulfanylméthyl-bicyclo[3.1.0]hexane 4-substitués en tant qu'antagonistes de mglur 2/3
MY178583A (en) Hydantoin derivative
CY1117011T1 (el) Παραγωγα αζολιου
TN2014000519A1 (en) Pyrimidinone derivatives as antimalarial agents
EA201390327A1 (ru) Гетероциклильные соединения в качестве лигандов гистаминовых hрецепторов
MX2013005050A (es) Derivados de indol.